Mineralys Therapeuticsの空売り状況は、投資家がMineralys Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Mineralys Therapeutics (NASDAQ:MLYS) 株価情報, 空売り情報

Mineralys Therapeutics

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics Inc

Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) has outperformed the market over the past 15 years by 7.37% on an annualized basis producing an average annual return of 18.42%. Currently, Arthur J. Gallagher has a market capitalization of $81.98 billion. 
Buying $1000 In AJG: If an investor had bought $1000 of AJG stock 15 years ago, it would be worth $12,711.30 today based on a price of $321.85 for AJG at the time of writing.
<h3>Arthur J. Gallagher's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741642226_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much You Would Have Made Owning Arthur J. Gallagher Stock In The Last 15 Years

Guidance

CVGI

Commercial Vehicle Group Expects 2025 Net Sales Of $670M - $710M, Est $691.85M

Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) cut its first-quarter revenue and profit guidance after Monday's closing bell sending a shockwave throughout<a href="https://www.benzinga.com/etfs/sector-etfs/25/03/44203960/aviation-etfs-face-turbulence-as-oil-prices-fluctuate-airline-stocks-slide"> the airline sector. </a>
The Details: Delta said it now expects to deliver total revenue growth for the March quarter of 3% to 4% year-over-year, down from earlier forecasts of 7% to 9% growth. The airline also reduced its expected EPS to between 30 cents and 50 cents per share, down from previous guidance of 70 cents to $1 per share. 
Read More:<a href="https://www.benzinga.com/general/market-summary/25/03/44227856/nasdaq-sp-500-hit-6-month-lows-as-recession-fears-grow-whats-driving-markets-monday"> Nasdaq, S&amp;P 500 Hit 6-Month Lows As Recession Fears Grow: What&#8217;s Driving Markets Monday?</a>
Delta said its outlook was impacted by recent declines in consumer confidence amid economic uncertainty leading to softness in domestic demand.&nbsp;
Delta Air Lines CEO Ed Bastian told CNBC that corporate and consumer spending have started to fall and recent air safety incidents have had an impact on bookings as well.&nbsp;
Airline Sector: Other airline stocks, including American Airlines Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) and United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) were also sharply lower following the announcement from Delta. 
Investors can monitor the airline industry though the U.S. Global Jets ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JETS#NYSE">JETS</a>), which provides diversified exposure to the global airline industry, including airline operators, aircraft manufacturers, airports and terminal services companies. 
DAL Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Delta Air Lines shares were down 13.09% at $43.74 after falling 5.51% during Monday's regular trading session. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying">Markets Tank After Trump Confirms More Tariffs: Here&#8217;s What Wall Street Is Saying</a></li>
</ul>
Photos: Shutterstock

Travel

Movers

General

JETS

Delta Air Lines Cuts Q1 Guidance Below Estimates: Airline Stocks Fall

HSAI

Hesai Group Expects FY25 Net Revenues Of RMB3.0B - 3.5B, With Adj Profitability Of RMB350M - 500M

Adjusted EBITDA for the year ending December 31, 2025 is expected to be in the range of $54 million to $58 million.

Viemed Healthcare Expects FY25 Net Revenue Of $254M -$265M, Est $251.50M

Redwire Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) shares are trading lower in Monday&#8217;s after-hours session on the heels of the company&#8217;s fourth-quarter financial results. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/03/b44235200/redwire-corporation-reports-fourth-quarter-and-full-year-2024-financial-results">of the report</a>.
<ul>
<li>Q4 Revenue: $69.56 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $74.82 million</li>
</ul>
<ul>
<li>Q4 EPS: Loss of $1.38, versus estimates for a loss of 18 cents</li>
</ul>
Total revenue was up 9.6% year-over-year in the fourth quarter. The company generated net cash from operations of $7.1 million and free cash flow of $3 million in the quarter.
Redwire ended the quarter with $64.1 million of total liquidity, including $33.7 million in cash and cash equivalents.
&#8220;Redwire continues to execute against its core business while moving up the value chain, supported by accretive M&amp;A. As a result, we have a strong and sustainable foundation for success in 2025,&#8221; said Peter Cannito, chairman and CEO of Redwire.
&#8220;We see strong demand for our products in space and defense tech and continue to differentiate ourselves&nbsp;in the market with innovative technologies and strong financial performance.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/25/03/44236027/oracle-q3-earnings-revenue-miss-eps-miss-backlog-booms-62-strong-ai-growth-expected-shares-climb">Oracle Q3 Earnings: Revenue Miss, EPS Miss, Backlog Booms 62%, Strong AI Growth Expected, Shares Climb</a>
Outlook: Redwire expects full-year 2025 revenue of $535 million to $605 million. The company anticipates full-year adjusted EBITDA of $70 million to $105 million, and positive free cash flow. 
Management will further discuss the quarter on a conference call Tuesday morning at 9 a.m. ET.
RDW Price Action: <a href="http://benzinga.com/quote/rdw">Redwire shares</a> were down 19.36% after hours, trading at $9.08 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
This illustration was generated using artificial intelligence via Midjourney.

Earnings

SPACE

After-Hours Center

Redwire Shares Tumble On Q4 Earnings Miss: The Details

PCOR

Procore Reaffirms Its Q1 And Full-year Fiscal 2025 Guidance

Management

Procore Founder, President And CEO Tooey Courtemanche Plans To Transition To Executive Chairman Upon Appointment Of Successor; Board To Begin Search Process

Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $1.42 by 88.03 percent. This is a 254.55 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $98.61 million which missed the analyst consensus estimate of $723.60 million by 86.37 percent. This is a 24.75 percent increase over sales of $79.04 million the same period last year.

Earnings Misses

Hesai Q4 Adj. EPS $0.17 Up From $(0.11) YoY, Sales $98.61M Up From $79.04M YoY

Alamos Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>) has outperformed the market over the past 5 years by 27.06% on an annualized basis producing an average annual return of 42.85%. Currently, Alamos Gold has a market capitalization of $9.75 billion. 
Buying $1000 In AGI: If an investor had bought $1000 of AGI stock 5 years ago, it would be worth $4,782.16 today based on a price of $23.18 for AGI at the time of writing.
<h3>Alamos Gold's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741641310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

RMBS

Rambus Unveils Its Next-generation CryptoManager Security IP Solutions, Including Root Of Trust, Hub And Core Families

The acquisition is expected to close in the second quarter of 2025, subject to customary closing conditions and regulatory approval.

Teradyne Agrees To Acquire Privately Held Photonic IC Testing Company Quantifi Photonics; No Terms Disclosed

Outlook
For the first quarter of 2025, Yalla currently expects revenues to be between US$75.0 million and US$82.0 million.
The above outlook is based on current market conditions and reflects the Company management's current and preliminary estimates of market and operating conditions and customer demand, which are all subject to change.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">
[6]&nbsp;Non-GAAP operating income represents operating income excluding share-based compensation. Non-GAAP operating income is a non-GAAP financial measure. See the sections entitled "Non-GAAP Financial Measures" and "Reconciliations of GAAP and Non-GAAP Results" for more information about the non-GAAP measures referred to in this press release.
[7] Non-GAAP earnings per ordinary share is non-GAAP net income attributable to Yalla Group Limited's shareholders, divided by weighted average number of basic and diluted shares outstanding. Non-GAAP net income attributable to Yalla Group Limited's shareholders represents net income attributable to Yalla Group Limited's shareholders, excluding share-based compensation. Non-GAAP earnings per ordinary share and non-GAAP net income attributable to Yalla Group Limited's shareholders are non-GAAP financial measures. See the sections entitled "Non-GAAP Financial Measures" and "Reconciliations of GAAP and Non-GAAP Results" for more information about the non-GAAP measures referred to in this press release.
</td>
</tr>
</tbody>
</table>
</figure>

YALA

Yalla Group Sees Q1 2025 Revenue $75M-$82M Vs $83.3M Est.

Across the recent three months, 9 analysts have shared their insights on Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Repay Holdings and provided 12-month price targets. The average target is $10.5, accompanied by a high estimate of $14.00 and a low estimate of $7.50. Experiencing a 9.56% decline, the current average is now lower than the previous average price target of $11.61. 
<img src="https://www.benzinga.com/files/images/story/2025/1741640666_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Repay Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Rufus Hone</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Timothy Chiodo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.50</td>
<td>$9.50</td>
</tr>
<tr>
<td>Charles Nabhan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Peter Heckmann</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Repay Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Repay Holdings compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Repay Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Repay Holdings's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RPAY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Repay Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Repay Holdings's Background</h2>
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
<h3>Unraveling the Financial Story of Repay Holdings</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Repay Holdings's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 3.01%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -5.26%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Repay Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.54% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Repay Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.26% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.67.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

RPAY

Expert Outlook: Repay Holdings Through The Eyes Of 9 Analysts

Throughout the last three months, 18 analysts have evaluated Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.22, along with a high estimate of $20.00 and a low estimate of $12.00. Highlighting a 19.13% decrease, the current average has fallen from the previous average price target of $18.82. 
<img src="https://www.benzinga.com/files/images/story/2025/1741640658_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Evolent Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>Citizens Capital Markets</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jeff Jones</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$16.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Evolent Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Evolent Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Evolent Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Evolent Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EVH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Evolent Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Evolent Health</h2>
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
<h3>Evolent Health's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Evolent Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.27% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Evolent Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -4.74%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Evolent Health's ROE stands out, surpassing industry averages. With an impressive ROE of -3.0%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Evolent Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.21% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Evolent Health's debt-to-equity ratio is below the industry average at 0.71, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 18 Analysts Discuss Evolent Health Stock

Across the recent three months, 4 analysts have shared their insights on Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $16.0, along with a high estimate of $19.00 and a low estimate of $13.00. Witnessing a positive shift, the current average has risen by 14.29% from the previous average price target of $14.00.
<img src="https://www.benzinga.com/files/images/story/2025/1741640648_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Zymeworks among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$18.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zymeworks. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Zymeworks compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Zymeworks's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Zymeworks's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZYME/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zymeworks analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Zymeworks</h2>
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
<h3>Breaking Down Zymeworks's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Zymeworks's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 83.33%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zymeworks's net margin excels beyond industry benchmarks, reaching -75.75%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Zymeworks's ROE excels beyond industry benchmarks, reaching -6.66%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Zymeworks's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -4.95%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.05, Zymeworks adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ZYME

Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings)

Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) reported quarterly earnings of $0.20 per share. This is a 5.26 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $90.83 million which beat the analyst consensus estimate of $83.22 million by 9.14 percent. This is a 12.24 percent increase over sales of $80.92 million the same period last year.

Earnings Beats

Yalla Group Q4 Adj $0.20 Up From $0.19 YoY, Sales $90.83M Beat $83.22M Estimate

In the last three months, 4 analysts have published ratings on Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Sun Communities, presenting an average target of $137.5, a high estimate of $142.00, and a low estimate of $131.00. A decline of 4.01% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741640639_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Sun Communities is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$142.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$142.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>James Feldman</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$135.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$131.00</td>
<td>$138.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sun Communities. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sun Communities compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sun Communities's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SUI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sun Communities analyst ratings.</a>
<h2>Delving into Sun Communities's Background</h2>
Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 666 properties, which includes 350 manufactured housing communities, 179 residential vehicle communities, and 137 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
<h3>A Deep Dive into Sun Communities's Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Sun Communities's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 2.59%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: Sun Communities's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -30.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -3.07%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Sun Communities's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.32%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Sun Communities's debt-to-equity ratio is below the industry average. With a ratio of 1.04, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 4 Analyst Ratings Have To Say About Sun Communities

Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) reported quarterly earnings of $0.10 per share which met the analyst consensus estimate. This is a 11.11 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $60.70 million which beat the analyst consensus estimate of $59.95 million by 1.24 percent. This is a 19.62 percent increase over sales of $50.74 million the same period last year.

Viemed Healthcare Q4 2024 GAAP EPS $0.10, Inline, Sales $60.70M Beat $59.95M Estimate

WIIM

ORCL

Oracle shares are trading higher after the company announced it will increase its quarterly dividend by $0.10 per share.

Press Releases

Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

Health Care

Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

MLYS

Abivax

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

AnaptysBio

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Erasca

Immatics

Keros Therapeutics

Kura Oncology

MeiraGTx Hldgs

Opthea Limited - American Depositary Shares

Opthea

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Precigen

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

PureTech Health plc - American Depositary Shares

PureTech Health

Relay Therapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sage Therapeutics

Sana Biotechnology

Savara

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tyra Biosciences

Upstream Bio

Valneva

HC Wainwright & Co.

Goldman Sachs

Credit Suisse

Wells Fargo

B of A Securities

Mineralys Therapeutics shares are trading higher after the company reported topline data from its pivotal LAUNCH-HTN Phase 3 and ADVANCE-HTN Phase 2 trials of Lorundrostat for hypertension. Both trials met the primary endpoint.

Comments

Mineralys Therapeutics

空売り

Mineralys Therapeutics (NASDAQ:MLYS) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル